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Back to the Future 
Thomas E. Starzl 
Between the ICTS Congress in Miami and this one in Vi-
enna, we have passed the half-century mark of what .has 
been considered the modern era of clinical transplantatIOn. 
All too often, the starting point of an era is arbitrary and 
decided upon by someone who believes the d~wn to be the 
moment of his or her arrival. With transplantatIOn, however, 
there seems to be little argument that the beginning should be 
dated to 1953. The following 51 years can be divided into four 
distinct phases. The protracted birth of clinical transplanta-
tion took place during the 15 years of Phase 1. 
Phase 1 
The birth began between 1953 and 1956 with the dem-
onstration that neonatal mice (1) and irradiated adult mice 
(2) developed donor specific tolerance after successful alloen-
graftment of splenic and bone marrow cells. Because a good 
histocompatibility match was required for avoidance of graft 
versus host disease (GVHD), clinical application of hema-
tolymphopoietic cell transplantation had to await discovery 
of the HLA antigens. When this was accomplished (3), the 
successfully-treated human bone marrow recipients of 1968 
were oversized versions of the tolerant chimeric mice. 
The clinical bone marrow transplant breakthrough of 
1968 (4-6) signaled the end of Phase l. In the meanwhile, all 
of the major struts of clinical organ transplantation had been 
put in place: immunosuppression, preservation, tissue 
matching, and the complex surgical technology. In fact, kid-
ney transplantation, which was first accomplished in humans 
nearly a decade before clinical bone marrow transplantation 
(7,8), already was an established clinical service by 1968, al-
beit a flawed one. And in addition, the first long survivals had 
been recorded after liver (9) and heart (10) transplantation. 
All of this had been accomplished in the ostensible absence of 
leukocyte chimerism, without HLA matching and with no 
evidence of graft versus host disease. 
Two unexplained features of the alloimmune re-
sponse had made it feasible to forge ahead precociously 
with organ transplantation. The first was the demonstra-
tion that organ rejection is highly reversible. The second 
observation was that an organ allograft, if protected by 
nonspecific immunosuppression, can induce variable spe-
cific tolerance. The tolerogenic quality of an organ allo-
graft was observed for the first time in any species in 1959 
in 2 fraternal twin kidney recipients, the first in Boston (7) 
and the second in Paris (8). The patients had been condi-
tioned with sublethal total body irradiation prior to trans-
plantation. Both renal allografts functioned for more than 
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two decades withSutDane~d for maintenance drug therapy 
which was; in fact, not yet available. 
.A similar drug-free state was next occasionally obser:ved 
after kidney transplantation, and more frequentl~ after .hver 
replacement, in mongrel dogs who were tre~ted With a smgle 
immunosuppressive agent: 6 mercaptopunne (6-MP), aza-
thioprine, prednisone, or ALG. After t~eat~ent was stopped, 
rejection did not develop for long penods 10 some ammals. 
Such results were at first exceedingly rare-no more than 1 or 
2% of the canine kidney experiments done under 6-MP and 
azathioprine up to the 'end of 1962. However, it was suspected 
by this time that rejection, its reversal, and immuno~uppres­
sion-assisted organ engraftment was a form of partIal toler-
ance. This view was crystallized by the human experience 
summarized in the title of a report in 1963 of a series of live 
donor kidney recipients treated in Denver: "The reversal of 
rejection in human renal homografts with subsequent devel-
opment of homograft tolerance" (11). 
The patients had beep treated witp azathioprine, add-
ing large doses of prednisone to treat rejections that were 
monitored by serial testing of serum creatinine (Fig. lA). Al-
though. rejection occurred in a~most every case, these were 
USLl<llly reversibfe. The one-year survival of 46 allografts from 
familial donors in 1962-63 was an unprecedented 75%. 
While most of the 25% loss was due to uncontrolled acute 
rejection, the development of partial tolerance in many of the 
survivors was inferred from the rapidly declining need for 
treatment after rejection reversal. In fact, nine ( 19%) of the 46 
familial allografts transplanted in Denver during this period 
functioned for the next four decades. Moreover, all immuno-
suppression eventually was stopped in seven of these nine 
patients without rejection, for periods ranging from 6 to 40 
years. Eight of the nine patients are still alive and bear the 
longest surviving organ allografts in the world (12). 
What was the connection between the tolerant mice, 
the irradiated fraternal twin kidney recipients in Boston and 
Paris, the canine organ recipients in whom treatment could 
be stopped, and the unique cluster of ultimately drug-free 
human kidney recipients in Colorado? The mystery deepened 
with the demonstration in 1966 in France (13) and England 
(14) that the liver can be transplanted in about 20% of out-
bred pigs without any treatment at all. None of the organ 
recipients, whether off or on maintenance immunosuppres-
sion, were thought to have donor leukocyte chimerism. Thus, 
organ transplantation became disconnected at. a v~ry early 
time from the scientific anchor of leukocyte chlmensm that 
had been established by the mouse models, and was soon to 
be exemplified by human bone marrow transplantation. The 
resulting intellectual separation of the two kinds of trans plan-
tation was an unchallenged legacy of Phase 1 passed on from 
generation to generation ever since. 
There was another dark legacy of Phase 1. This was a 
modified version of the treatment strategy developed with 
azathioprine and prednisone. The principal changes from the 
original protocol are shown in Figure 1 B. Instead of supple-
menting baseline immunosuppression only when needed as 
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nGURE 1. The role of immunosuppression in deletiona! tolerance. Exhaustion and deletion of the antigraft response 
occurs without any treatment in spontaneous tolerance models (usually liver transplantation). (A) In normally rejecting 
models, the recipient response may be kept in the deletable range with just the right daily doses of minimal immunosup-
pression (gray bar), permitting the development of variable tolerance. Because accurate prediction of the "right dose" in 
the outbred human population is not possible, dose maneuverability is required. (B) Prophylactic posttransplant overim-
munosuppression with multiple drugs (layered bars) with variable subversion of clona! activation &U279C; exhaustion 
&U279C; deletion. (C) Reduction of the anticipated antidonor response into a dele table range by lowering global immune 
reactivity before exposure to alloantigen with pretransplant cytoablation or cytoreduction. (D) Combined use of the ther-
apeutic principles depicted in (A) and (C). 
shown in Figure lA, large prophylactic doses of prednisone 
were administered from the time of transplantation. This was 
an instinctive reaction to the loss of grafts to rejections that 
could not be reversed. With this change, the incidence of 
acute rejection was greatly reduced. i\lore than 35 years 
passed before the long term immunologic consequences of 
the modifications were realized. 
Thus, by 1968 the foundation, as well as the essential 
superstructure of clinical transplantation as we know it today, 
had been established. :--..lot surprisingly, all 19 recipients to 
date of the Medawar prize served as midwives during the 
IS-year birth period of 1953-1968. The role of 12 of the 19 
laureates in the ascension of the tissue matching-dependent 
bone marrow transplantation from mOllse to man (Table I, 
left) is easy to identify. By going beyond the boundaries es-
tablished by the mouse models, the seven contributors to or-
gan transplantation (Table J, right) had wandered into a new 
conceptual universe. 
Phase 2 
Throughout the succeeding Phase 2 that began in 1969, 
immunosuppression for organ transplantation was based on 
azathioprine, and in most centers, prophylactic high doses of 
prednisone or posttransplant antilymphocyte globulin (ALG) 
which had been introduced clinically in 1966. It was a bleak pe-
riod. In the view of critics, the heavy mortality, and particularly 
TABLE 1. Medawar Laureates 
Bone marrow-oriented (n=12) 
Bach, F.H. 
Billingham, R.E. 
Brent, L.B. 
Dausset, LB.' 
Gowans, J.L. 
Mathe, G. 
Miller, J.F.A.P. 
Owen, R.D. 
Rapaport, F.T. * 
Simonsen, M. 
Terasaki, P.1. * 
van Rood, J.J.' 
• HI.A typing pioneers. 
Organ-oriented (n=7) 
Caine, R.Y. 
Kiiss, R. 
Monaco, A.P. 
Murray, J.E. 
Schwartz, R.S. 
Shumway, N.E. 
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the devastating morbidity callsed by slcroid dependence, made 
organ transplantation (even of kidneys) as much a disease as a 
treatment. Most of the liver and heart transplant programs that 
had been established in the' lalL" I %05, in an initial burst of opti-
mism, closed down. But in tht' few th,1t remained, a trickle of 
long-surviving liver and heart recipients bore witness to what 
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some day would be accomplished on a grand scale. For example, 
a woman now in her 36th posttransplant year was 4 years old at 
the time of liver replacement in Denver for biliary atresia and a 
hepatoma. She is the longest surviving recipient in the world of 
an extra rena I organ. 
Phase 3 
I n fact, what had appeared to be the sunset of extrarenal 
transplantation was only the dawn of Phase 3. Phase 3 began 
with the clinical introduction of cyclosporine (15), followed a 
decade later by tacrolimus (16). These drugs were associated 
with stepwise improvements with all kinds of organ transplan-
tation. BlIt their impact was most conclusively demonstrated 
with liver and heart transplantation. As new agents became avail-
able, they were simply folded into the modified formula ofheaV)' 
prophylactic immunosuppression that had been inherited from 
Phases I and 2 (Fig. I B) . Used in this way, the better drugs fueled 
the golden age of transplan tation of the I980s and early 1990s. 
Acute rejection had become almost a nonproblem. However, the 
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unresolved issues now were chronic rejection, risks of/ong term 
immunodepression per se and drug-specific side effects. It was 
clear that amelioration of these problems would require, as a first 
step, elucidation of the mechanisms of alioengraftment and of 
acquired tolerance. 
Phase 4 
An intensified search for these immunologic mecha-
nisms became the theme of our current Phase 4, which began 
in earnest about a dozen years ago. Until this time, organ 
engraftment had been attributed to mechanisms that did not 
involve either the presence or a role of donor leukocyte chi-
merism. It was known that organs contain large numbers of 
passenger leukocytes, and that these donor cells were largely 
replaced in the successful transplanted allograft by recipient 
leukocytes (Fig. 2A). However, the missing donor cells were 
thought to have undergone immune destruction with selec-
tive sparing of the specialized parenchymal cells. Conversely, 
the ideal result after bone marrow transplantation was gener-
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FIGURE 2. Old (A and B) and new views (C and D) of transplantation recipients. (A) The early conceptualization of immune 
mechanisms in organ transplantation in terms of a unidirectional host versus graft (HVG) response. Although this readily ex-
plained organ rejection, it limited possible explanations of organ engraftrnent. (B) Mirror image of (A) depicting the historical 
view of successful bone marrow transplantation as a complete replacement of the recipient immune system by that of the donor, 
with the potential complication of an unopposed lethal unidirectional graft versus host (GVH) response (i.e., rejection of the 
recipient by the graft.) (C) Our current view of bidirectional and reciprocally modulating immune responses of coexisting 
immune competent cell populations . Because of variable reciprocal induction of deletional tolerance, organ engraftment was 
feasible despite a usually dominant HVG reaction. The bone silhouette in the graft represents passenger leukocytes of bone 
marrow origin. (D) Mirror image of (C) after successful bone marrow transplantation. Recipient cytoablation has caused a 
reversal of the size proportions of the donor and recipient populations of immune cells. Reprinted with permission from (31). 
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ally perceived as complete replacement of recipient immune 
cells (i.e., total hematolymphopoietic chimerism; Fig. 2B). 
A flaw in this historical dogma began to be exposed in 
the early 1990s with the puzzling observation in Seattle that 
there always was a small residual population of recipient he-
matolymphopoietic cells in patients previously thought to 
have complete bone marrow replacement (Fig. 2D) (17). 
When a similar small population of donor leukocytes (i .e., 
microchimerism) was discovered with sensitive detection 
techniques in 1992 in long-surviving human recipients of 
functioning organ allografts (Fig. 2C), it was evident that or-
gan engraftment and bone marrow cell engraftment were 
mirror image versions of leukocyte chimerism (18-20). The 
microchimerism was demonstrated in the blood, lymph 
nodes, skin, or other tissues of aU 30 liver or kidney recipients 
studied up to three decades after transplantation. The donor 
hematolymphopoietic cells were of different lineages includ -
ing dendritic cells. 
The peripheralized donor leukocytes obviously were 
progeny of migratory donor precursor or pluripotent hema-
tolymphopoietic stem celJs that were a normal constituency of 
whole organs. From the biopsy findings and from voluminous 
Supp0l1ing data, we concluded that organ engraftment had re-
sulted from " .. .. responses of co-existing donor and recipient 
cells, each to the other, causing reciprocal clonal exhaustion , fol-
lowed by peripheral clonal deletion " (18,19). The host response 
was the dominant one in most cases of organ transplantation, 
but with the occasional exception of GVHD (Fig. 3). In the con-
ventionally treated bone marrow recipient, host cytoablation 
simply transferred immune dominance from the host to the 
graft, explaining the high risk of GVHD. AU of the major differ-
ences between the two kinds of transplantation were caused by 
the recipient cytoablation (18-20). 
Although this explanation of alloengraftment was con-
gruent with essentially all previously enigmatic observations 
in experimental and clinical models of transplantation, it was, 
at first, highly controversial. The criticisms were dampened in 
the mid-1990s with the demonstration by Zinkernagel that 
the different carrier states caused by spreading noncytopathic 
Immune ic::~-::;:;:--::;:;:=::=====~~~~~::::::::;::::::;;;~pucceRs Reaction r 
Time after Organ Transplantation 
nGURE 3. Contemporaneous host-versus-graft (HVG) 
(upright curves) and graft-versus-host (GVH) (inverted 
curves) responses following organ transplantation. If some 
degree of reciprocal clonal exhaustion is not induced and 
maintained (usually requiring protective immune suppres-
sion) , one cell population will destroy the other. In contrast 
to the usually dominant HVG reaction of organ transplanta-
tion (shown here), the GVH reaction usually is dominant in 
the cytoablated bone marrow recipient. Therapeutic fail-
ure with either type of transplantation implies the inability 
to control one, the other, or both of the responses. Re-
printed with permission from (24). 
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microorganisms represented various levels of similar dele-
tional tolerance (21-23). After agreeing that the kinetics and 
mechanisms of infection tolerance were essentially the same 
as those of alloengraftment, Zinkernagel and I undertook a 
review in which the analogies between the numerous clinical 
scenarios of transplantation and those of infectious diseases 
were described (24 ). We also proposed that the migration and 
localization of antigen are the principal factors governing im-
munologic responsiveness or unresponsiveness, no matter 
what the antigen. 
One key tenet of this immunoregulatory paradigm is 
that the presence of antigen that fails to reach lymphoid destina -
tions is not recognized (immune ignorance) . The other is that 
clonal exhaustion-deletion is the seminal mechanism of ac-
quired tolerance. The existence and importance of immune 
ignorance (25,26) and of clonal exhaustion-deletion (27,28) 
were formally proved in the 1990s. After organ transplantation, 
the prompt recognition of alJoantigen is assured when the pas-
senger leukocytes of the graft simulate the hematogenous spread 
of noncytopathic microorganisms (e.g., the hepatitis viruses) 
and migrate preferentially to host lymphoid organs (Fig. 4, left). 
There they induce a cytolytic T cell response before disseminat-
ing more ubiquitously (Fig. 4, right). Cells that reach protected 
nonlymphoid niches may subsequently migrate back to host 
lymphoid organs and maintain the deletional state induced at 
the outset. Alternatively, these donor cells may perpetuate allo-
immunity in the same way as residual microorganisms sustain 
protective inlmunity: that is, below some threshold, microchi-
merism may be responsible for the high PRA or other evidence 
of sensitization that frequently develops after unsuccessful 
transplantation. 
How could this insight be exploited clinically? This was 
considered in a second review (29). The window of opportu-
nity for the clonal deletion that results in the coJlapse of the 
immune response shown in Figure 1A and Figure 3 is open 
FIGURE 4. Initial preferential migration of passenger 
leukocytes from organ allografts to host lymphoid organs 
(left), where they induce a donor-specific immune re-
sponse. After about 30 days, many of the surviving cells 
move on to nonlymphoid sites (right). Migration from these 
privileged locations back into the lymphoid compartment 
may perpetuate the exhaustion-deletion induced at the out-
set, or alternatively, initiate (or maintain) alloimmunity. Re-
printed with permission from (32). 
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only for the first few posttransplant weeks of maximal donor 
leukocyte migration. It was apparent that the window could be 
closed by excessive postoperative immunosuppression (Fig. 1 B). 
With later reduction of the initial over immunosuppression, re-
covery of the inefficiently deleted clone would lead to the delayed 
acute rejection, or the chronic rejection, that were being seen in 
the transplant clinics (Fig. 1 B). Even in the best case scenario, the 
patients would be predestined to lifetime dependence on im-
munosuppression. However, too little immunosuppression 
would result in uncontrolled rejection. 
In 2001, it was suggested that this dilemma could be 
addressed by adherence to the two historically rooted thera-
peutic principles shown on Figure 1: recipient pretreatment 
and minimalistic posttransplant immunosuppression (29). 
Minimal immunosuppression alone (Fig. lA) can allow the 
development of tolerance, but it is difficult to use this ap-
proach in the heterogeneous outbred human population. 
With pretreatment (Fig. IB), the recipient's global immune 
responsiveness is reduced before exposure to donor antigen, 
thereby lowering the anticipated donor-specific response into 
a more readily delectable range (Fig. lC). This apparently is 
what had been accomplished with sublethal irradiation alone 
in the ground-breaking fraternal twin cases of 1959 (7,8). In 
fact, pretreatment by recipient cytoablation became the es-
sential therapeutic step in conventional bone marrow trans-
plantation, but with the penalty of graft versus host disease 
even with an HLA-matched donor. Irradiation and other cy-
toablation methods were too dangerous and too restrictive 
because of the prerequisite HLA matching to be used for or-
gan transplantation. 
However, less drastic lymphoid depletion by ALG or 
other well known measures (the so-called nonmyeloablative 
approach) has been repeatedly shown to be effective without 
causing GVHD. Consequently, we suggested that pretreat-
ment with one of today's potent antilymphoid antibody prep-
arations combined with just the right amount of post-trans-
plant immunosuppression would allow the preemptively 
weakened clonal activation to proceed efficiently to clonal 
deletion (Fig. ID). The ultimate objective was to reduce long 
term dependence on maintenance therapy. This was not a 
new idea. Precisely this strategy was extensively tested in the 
late 19605 and was one of the principal topics of a CIBA Foun-
dation symposium in January 1967 (30) which was attended 
by several members of today's audience. However, the strat-
egy could not be efficiently applied with a baseline agent as 
weak as azathioprine. Moreover, it had been developed 
empirically without an understanding of the mechanisms 
of alloengraftment. 
With elucidation of engraftment mechanisms, and 
armed with today's better drugs, definitive studies of varia-
tions of the lymphoid depletion strategy are ongoing at sev-
eral centers. Patient and graft survival are the parameters of 
greatest immediate interest. However, these trials constitute 
formal tests of immunologic hypotheses and thus should help 
bring to closure long-standing disputes about the biologic 
meaning and mechanisms of acquired tolerance. Although 
our view is that clonal exhaustion-deletion and immune ig-
norance are the seminal mechanisms of allotolerance, and 
that both are regulated by the migration and localization of 
leukocytes (24,29), other proposed primary or accessory 
mechanisms may playa role. Singly or together these altern a-
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tive immunoregulatory mechanisms may be important. In-
tense efforts are currently being made to determine if, or to 
what extent, they can be used to design or guide clinical care. 
Such research is well represented on the congress pro-
gram. Thus, this 20th Congress of our Society may well be 
remembered as the beginning of the end of Phase 4. If so, it is 
fitting that the page should be turned to a new chapter in 
Vienna, where 102 years ago, Emerich Ullmann reported to 
the Vienna Medical Society the transplantation of kidney al-
lografts into the neck of dogs. These first attempts in history 
to transplant an organ in any species were celebrated in the 
centennial symposium organized here in 2002 by our host, 
Raimund Margreiter. . 
What lies ahead in Phase 5? My predication is that com-
pletely drug-free tolerance will be largely, but not exclusively, 
limited to recipients ofHLA-matched organs. But variable par-
tial tolerance is there for the taking in most of the others, allow-
ing reduced exposure to the risks of chronic immunosuppres-
sion. Xenotransplantation will have to be developed within the 
same immunologic framework. Here, the problem, in principle, 
is to create a better inter-species tissue match by transgenic mod-
ification. Although the a-Gal gene has been knocked out in pigs, 
it is not yet known what further changes must be made. Where 
stem cell biology will fit remains unknown. But it also will have 
to conform to the same immunologic rules. 
One thing seems to me certain. Our forefather and 
founding president, Peter Medawar, would be moved inde-
scribably if he could see the extent to which his chimerism 
discoveries with Billingham and Brent (1) have been the glue 
seamlessly uniting not only all of experimental and clinical 
transplantation, but also linking transplantation to other 
fields of experimental and applied immunology. He also 
would smile if he could see that progress is now being made 
not so much by developing better drugs as by the better use of 
drugs we already have in hand. 
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